News Johnson & Johnson Buenos Aires S.E.

Equities

JNJD

ARDEUT110236

End-of-day quote Buenos Aires S.E. Other stock markets 06:00:00 2024-07-04 pm EDT			5-day change	1st Jan Change
9.85 ^USD	-0.51%		-1.20%	-3.43%

Jul. 03	Johnson & Johnson's Rybrevant Approved by Health Canada to Treat Advanced Lung Cancer	MT
Jul. 03	Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Johnson & Johnson's Rybrevant Approved by Health Canada to Treat Advanced Lung Cancer	Jul. 03	MT
Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval	Jul. 03	DJ
Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	Jul. 03	AQ
J&J: full approval for Sirturo in tuberculosis	Jul. 03	CF
J&J: promising results in multiple myeloma	Jul. 02	CF
Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise	Jul. 02	MT
Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI	Jul. 02	CI
State AG Updates: June 6-13, 2024	Jul. 02	AQ
Momentum Picks Q3 2024: 5 stocks for the summer	Jul. 01
CHMP adopts positive opinion for BALVERSA for the treatment of adult patients	Jul. 01	AQ
Johnson & Johnson - Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class	Jul. 01	AQ
New semester, new state of mind	Jul. 01
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients	Jun. 28	PU
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	Jun. 28	MT
J&J Unit's Rybrevant Combo Gets EU Approval	Jun. 28	MT
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients	Jun. 28	PR
Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study	Jun. 28	CI
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations	Jun. 28	PU
Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma	Jun. 28	MT
Dealmakers optimistic on global M&A prospects despite sluggish growth	Jun. 28	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST